Lessons learned from the reimbursement policy for immune checkpoint inhibitors and real-world data collection in Taiwan

Int J Technol Assess Health Care. 2020 Dec 21:37:e26. doi: 10.1017/S0266462320002160.

Abstract

This paper describes the reimbursement policy for immune checkpoint inhibitors in Taiwan and provides a perspective to improve the quality, consistency, and transparency of decision making. Global trends for cancer treatment have shifted from chemotherapies to targeted therapies and immuno-oncology (IO) medicine, leading to significant increases in treatment costs. To enhance the accessibility of advanced therapy, the Taiwan National Health Insurance Administration announced two pathways for high-cost medicine: the managed entry agreement and a set of general rules of reimbursement submission for high-cost drugs. To further manage the financial burden on Taiwan's national health insurance system, the policy makers introduced novel inhibitory drugs for cancer immune checkpoints, subject to a maximum annual budget of NT$800 million (≈US$26.7 million). In April 2019, a national registry was established for patients undergoing cancer immunotherapy. Clinical characteristics, treatment duration, toxicity, and the outcome of the postcheckpoint inhibitor treatments were recorded. By analyzing real-world data, we assess the therapeutic effect of IO treatment in Taiwanese patients, thereby enabling payers to adjust payment regulations and rules for reimbursement. The Health Technology Assessment Team plays an important role in drawing upon the evidence to support policy making. Under an implemented cost-management mechanism, Taiwan's high-cost drug policy has enabled patients to access new medicines and maximized patient benefits.

Keywords: Health technology assessment; Immune checkpoint inhibitors; National health insurance; Real-world data.

MeSH terms

  • Economics, Pharmaceutical*
  • Humans
  • Immune Checkpoint Inhibitors / economics*
  • Immune Checkpoint Inhibitors / therapeutic use
  • Insurance, Health, Reimbursement*
  • National Health Programs
  • Organizational Policy*
  • Taiwan
  • Technology Assessment, Biomedical

Substances

  • Immune Checkpoint Inhibitors